x
CME-Tagline

Examining the Latest Evidence on EDS and Cataplexy in Narcolepsy: What are the Implications for Your Practice?

CMEO Podcast

Premiere Date: Wednesday, December 29, 2021

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Medicine (accme)
  3. Nursing (ANCC)
  4. Pharmacy (acpe)
  5. PA (aapa)
  6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, December 29, 2022

Faculty


Michael J. Thorpy, MD Michael J. Thorpy, MD 
Professor of Neurology
Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
Bronx, NY
President, New York State Society of Sleep Medicine
Past President of the Sleep Section, Academy of Neurology

Yves Dauvilliers, MD, PhD Yves Dauvilliers, MD, PhD 
Professor of Neurology and Physiology
University of Montpellier
Director, Sleep-Wake Disorders Centre
Department of Neurology
Gui de Chauliac Hospital
Montpellier, France

Statement of Need

Treatment planning in patients with narcolepsy-associated excessive daytime sleepiness (EDS) and cataplexy is many-faceted, as it is important to not just reduce EDS and control cataplexy, nightmares and hallucinations, sleep paralysis, and disturbed nocturnal sleep (DNS) but to also improve the patient’s psychosocial dysfunction and quality of life (QOL), their safety and that of the public, and to optimize the risks and benefits of pharmacotherapies. It is imperative that clinicians identify individual goals for patients with narcolepsy and utilize the latest clinical data to develop personalized treatment plans.

This CME Outfitters podcast will focus on considering individual patient characteristics along with updated clinical parameters and newly approved narcolepsy medications so that clinicians can identify and implement effective treatment to achieve long-term benefits by improving clinical outcomes and therefore patient QOL.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Utilize the latest clinical evidence to guide treatment planning for adults with EDS and cataplexy associated with narcolepsy.

Financial Support

Supported by an educational grant from Harmony Biosciences, LLC.

Target Audience

Psychiatrists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Thorpy reports that he is a consultant and on the advisory board for Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Flamel Technologies/Avadel; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; NLS Pharmaceutics; Suven Life Sciences Limited; Takeda Pharmaceutical Company Limited; and XWPharma.

Dr. Dauvilliers reports that he is a consultant for Avadel; Bioprojet; Idorsia Pharmaceuticals Ltd; Jazz Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Theranexus; and UCB S.A., Belgium.

S. Michelle Franks, MSN, APRN, FNP-BC (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Susan H Yarbrough, CHCP (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

PD-078-122921-75